Catalyst Wire Dossier Catalyst Wire Dossier
FDA approval · 2022-01-20

FDA Approved: DOVATO — Supplemental Application (ViiV Healthcare Company)

View source ↗

Summary

FDA approved a supplemental NDA for Dovato (dolutegravir and lamivudine) from ViiV Healthcare Company. This action approves a modification/expansion to the prod…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Dovato (dolutegravir/lamivudine)

Snippet

SUPPL AP for DOVATO (DOLUTEGRAVIR SODIUM AND LAMIVUDINE)